Praesidia Biotherapeutics, Inc. — Form D/A
Praesidia Biotherapeutics, Inc. of ARLINGTON, MA, a company, filed a Form D amendment with the SEC on 2022-08-23. The offering totals $10.0M, of which $4.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-08-23
- Form: D/A
- Accession: 0001877990-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $10.0M
- Amount sold: $4.0M
- Remaining: $6.0M
- Investors: 55
- Date of first sale: 2021-07-30
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-409716
Issuer
- Name: Praesidia Biotherapeutics, Inc.
- CIK: 0001877990
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 1167 MASSACHUSETTS AVE., ARLINGTON, MA, 02476
- Phone: 6179775445
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| John Ripple | Director | Waltham, MA |
| Sohang Chatterjee | Director | Arlington, MA |
| Sohang Chatterjee | Executive Officer | Arlington, MA |
| Shawn Titcomb | Director | Sea Ranch Lakes, FL |
| Pradip Majumder | Executive Officer | Arlington, MA |
| Martin Lehr | Director | Arlington, MA |
Other filings by this issuer (4)
More